Article

New opportunities for medicines in Europe? How JCA and Project Orbis may impact the revenue potential of innovative medicines

  • Headshot of Claudio Valenti

    Claudio Valenti, MA

  • headshot

    David Ringger, PHD

A key objective of the Joint Clinical Assessment (JCA) and Project Orbis is to accelerate patient access to innovative medicines. While this goal has been widely examined, there has been relatively little discussion about the impact of these initiatives on the revenue potential of new products. This article explores how JCA and Project Orbis may influence the European revenue landscape for oncology treatments, providing deeper insights into their financial implications for manufacturers.

JCA and Project Orbis: Accelerating Patient Access to Oncology Treatments Across Europe

HTAQ Summer 2025
HTAQ Summer 2025
The introduction of Joint Clinical Assessment (JCA) and Project Orbis marks two of the most anticipated and widely discussed initiatives in recent years. These initiatives aim to enhance efficiency in regulatory, pricing, and reimbursement processes by streamlining assessments, minimising duplication, and reducing fragmented decision-making.

While extensive research has explored their impact on key industry factors—such as time to market (TTM) and medicine availability—their financial implications, particularly their impact on medicine revenue, have received comparatively less attention. Understanding these commercial effects is crucial, as expedited approvals and broader access can unlock new revenue opportunities while also introducing pricing challenges due to international reference pricing (IRP) practices commonly applied across Europe.
HTAQ Summer 2025

Overview of JCA and Project Orbis

JCA
JCA is designed to evaluate the efficacy and safety of new products through a collaborative, harmonised approach across European Union (EU ) member states. Since January 2025, JCA is mandatory for all oncology and advanced therapy medicinal products (ATMPs). European Medicines Agency (EMA) orphan-designated products will be included by 2028, followed by all EMA-registered products by 2030. This initiative directly impacts all EU27 member states, Norway, and Iceland.

Project Orbis
Project Orbis facilitates the simultaneous submission and review of oncology products among international regulatory partners. Led by the United States Food and Drug Administration (FDA), its primary goal is to accelerate patient access to innovative cancer treatments that offer clinical advantages over existing therapies. Participating European regulatory authorities include the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) and Switzerland (Swissmedic).
Calculator beside a pen and financial analysis paper

Quantifying the Revenue Impact

To assess the financial implications of JCA and Project Orbis on oncology product launches, we conducted a comprehensive revenue analysis across 27 EU member states (excluding Malta), as well as Norway, Switzerland, and the UK.

Our approach compared revenue projections under a pre-JCA and Project Orbis scenario—representing traditional regulatory and reimbursement pathways—with 5 alternative launch scenarios. Each scenario incorporated different assumptions regarding how JCA and Project Orbis influence TTM in each country and revenue generation.

Pre-JCA and Project Orbis Scenario

Revenue potential before the introduction of JCA and Project Orbis was estimated based on 48 oncology products approved in Europe between 2019 and 2022 that did not participate in Project Orbis. TTM was defined as the number of days between marketing authorisation and patient availability in each country. Revenue projections over a 5-year period considered the list prices, market size, and IRP rules:

  • TTM was based on the EFPIA WAIT report
  • List prices for each country were determined based on the median annual treatment cost of the oncology products. Due to the complexities of pricing dynamics and the impact of non-transparent discounts, this analysis relies on list prices rather than net prices to ensure consistency in evaluation.
  • European market size estimates, considering the population and per capita oncology expenditure.
  • IRP applications at launch and post-launch, following data from the Navlin IRP matrix.
 

JCA and Project Orbis Scenario

Our base-case scenario assumes that JCA could accelerate TTM by 25% across most EU countries. However, in markets that typically submit immediately following the Committee for Medicinal Products for Human Use (CHMP) opinion, delays of up to 3 months may occur.

To evaluate the impact of varying acceleration rates, we conducted a sensitivity analysis, assessing revenue implications for TTM acceleration ranging from 10% to 40%.

Under Project Orbis, we estimate that Switzerland could experience TTM accelerations of up to 7 months—an assumption based on the submission gap and review times for oncology products under Project Orbis vs non-Project Orbis pathways in Switzerland. However, we do not anticipate any changes for the UK since it is unclear whether the UK regulatory timeline is truly expedited with Project Orbis. (see Table 1).

Table 1. Summary of TTM scenario

Scenario
TTM

Pre-JCA and Project Orbis

Median of the TTM of the 48 oncology products launched in Europe between 2019 and 2022

Scenario 1

UK: No change in TTM

CH: 7 months accelerated TTM

BE, NE, DK, ES: 10% accelerated TTM + 100 days

Other countries: 10% accelerated TTM

Scenario 2

UK: No change in TTM

CH: 7 months accelerated TTM

BE, NE, DK, ES: 20% accelerated TTM + 100 days

Other countries: 20% accelerated TTM

Scenario 3

(Base-case scenario)

UK: No change in TTM

CH: 7 months accelerated TTM

BE, NE, DK, ES: 25% accelerated TTM scenario + 100 days

Other countries: 25% accelerated TTM

Scenario 4

UK: No change in TTM

CH: 7 months accelerated TTM

BE, NE, DK, ES: 30% accelerated TTM + 100 days

Other countries: 30% accelerated TTM

Scenario 5

UK: No change in TTM

CH: 7 months accelerated TTM

BE, NE, DK, ES: 40% accelerated TTM + 100 days

Other countries: 40% accelerated TTM


Key: BE: Belgium; CH: Switzerland; DK: Denmark; ES: Spain; JCA: Joint Clinical Assessment; NE: the Netherlands; TTM: time to market; UK: United Kingdom.

 

Revenue Calculations


Using our internal revenue calculator, we conducted a comprehensive 5-year revenue projection for each scenario and compared the results against the scenario pre-JCA and Project Orbis.

Our analysis indicates that while accelerated product launches lead to modest yet noticeable price erosion (Chart 1), the advantages outweigh the drawbacks. Faster market entry enables the capture of a larger market share within a shorter time frame, ultimately boosting overall profitability (Chart 2).

Furthermore, our revenue sensitivity analysis across these scenarios revealed a potential 14% revenue increase, underscoring the potential financial benefits of an expedited launch strategy.
Chart 1. Product price comparison of each scenario against the base case, applying pre- and post-launch IRP rules

HTAQ Summer 2025
Key: IRP: international reference pricing; JCA: Joint Clinical Assessment.
Chart 2. Revenue comparison of each scenario against the base case


HTAQ Summer 2025
Key: JCA: Joint Clinical Assessment.

Conclusions

Our analysis indicates that JCA and Project Orbis present a valuable opportunity for manufacturers to enhance revenue potential for newly launched oncology products in Europe.

While faster price erosion remains a consideration, the increased sales volume offsets this risk over a 5-year period. As a result, manufacturers adopting expedited launch strategies under JCA and Project Orbis stand to gain financial advantages while ensuring broader access to life-saving therapies.

Limitations of our analyses

The analysis has several important limitations:

  •  Revenue calculation: Revenues are estimated using list prices rather than net prices, as net prices for pharmaceuticals are heavily influenced by confidential agreements and undisclosed discounts. To ensure consistency, potential revenues are assessed based on publicly available list prices.
  • Baseline TTM: The estimated TTM for the UK and Switzerland prior to JCA and Project Orbis may differ slightly from this analysis’s assumptions. This variation arises because nine of the 48 products used to assess country-specific TTM were evaluated through Project Orbis.
  • IRP considerations: Both formal and informal IRP rules have been taken into account. However, informal IRP rules are challenging to evaluate due to inconsistent implementation. Assumptions were made to estimate the extent to which these informal pricing policies are applied.

 

This article summarises Cencora’s understanding of the topic based on publicly available information at the time of writing (see listed sources) and the authors’ expertise in this area. Any recommendations provided in the article may not be applicable to all situations and do not constitute legal advice; readers should not rely on the article in making decisions related to the topics discussed.

Connect with our team

Our team of leading value experts is dedicated to transforming evidence, policy insights, and market intelligence into effective global market access strategies. Let us help you navigate today’s complex healthcare landscape with confidence. Reach out to discover how we can support your goals.

 

Sources

  • European Federation of Pharmaceutical Products (EFPI). Patients W.A.I.T. Indicator 2023 Survey. June 2024. https://efpia.eu/media/vtapbere/efpia-patient-wait-indicator-2024.pdf
  • European Union. Joint Clinical Assessment for Medicinal Products. January 2025. https://health.ec.europa.eu/document/download/ced91156-ffe1-472d-85eb-aa6a91dd707e_en?filename=hta_htar_factsheet-jca_en.pdf
  • Government of the United Kingdom. Guidance on Project Orbis. Last updated 10 January 2025. https://www.gov.uk/guidance/guidance-on-project-orbis
  • European Medicines Agency. National competent authorities (human). https://www.ema.europa.eu/en/partners-networks/eu-partners/eu-member-states/national-competent-authorities-human
  • World Bank. Population total. Last updated 16 December 2024.  https://data.worldbank.org/indicator/SP.POP.TOTL
  • Cost of treatment. 31 December 2024. Retrieved from Navlin database.
  • International reference pricing rules. 31 December 2024. Retrieved from Navlin database.
  • Vrdoljak E, Bodoky G, Jassem J, et al. Expenditures on oncology drugs and cancer mortality-to-incidence ratio in Central and Eastern Europe. Oncologist. 2019;24(1):e30-e37. doi:10.1634/theoncologist.2018-0093. https://pmc.ncbi.nlm.nih.gov/articles/PMC6324644/
  • Swissmedic. Project Orbis: quicker access to promising cancer treatments. 29 May 2024. https://www.swissmedic.ch/swissmedic/en/home/news/mitteilungen/project-orbis-schnellerer-zugang-krebsbehandlungen.html
  • Precision Advisors. The post-Brexit UK access landscape: does Project Orbis significantly accelerate patient access for oncology drugs in the UK versus Europe? 2023. https://www.ispor.org/docs/default-source/intl2023/ispor23kennedyposter-project-orbis-pdf.pdf?sfvrsn=edc15b3_0
 

Related resources

Article

Tips for partnering with health systems: A critical step for CGT commercialization
World Courier team member presents at  a large LED digital display

Webinar

Navigating the healthcare policy landscape: Key insights for managed care and the life sciences industry
people working around a table

Article

Building revenue with mature products in a time of market flux

Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.

Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.